
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is a biotech company with a promising outlook due to a strong balance sheet, recent funding, and multiple ongoing clinical trials for its flagship products Ampligen and Alferon N Injection. Despite a lowered price target, analysts maintain a BUY rating for AIM based on its potential for growth and success in treating currently unmet medical needs. Positive clinical trial data for Ampligen in pancreatic and metastatic breast and colorectal cancers indicate the potential for high rewards in a billion dollar market, although there are still risks to achieving these goals in the long term.
Bears say
AIM ImmunoTech is a biopharmaceutical company with a negative outlook due to its limited cash reserves, high debt levels, and consistent net losses. While maintaining a BUY rating, analysts have lowered their 12-month price target to $22 based on NPV analysis, reflecting the company's high risks despite its growth prospects and potential for upside. The recent Q4 2025 results also fell below expectations with a higher-than-expected net loss, signaling uncertainties in the company's early/clinical stage drug development. Overall, there are significant fundamental concerns surrounding AIM ImmunoTech's financials and performance which may limit its potential for long-term success.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares